The neuroendocrine system as a model to evaluate experimental gene therapy.

The implementation of experimental gene therapy in animal models of neurological diseases is an area of growing interest. Although the neuroendocrine system offers unique advantages for the assessment of in vivo gene therapy, little work has been done in this model. Here we review the core of documented studies in which in vivo gene therapy has been implemented in the neuroendocrine system of rodent models. In the hypothalamus, restorative gene therapy has been successfully implemented in Brattleboro rats, an arginine vasopressin (AVP) mutant which suffers from diabetes insipidus, in Koletsky (fa(k)/fa(k)) and in Zucker (fa/fa) rats which have leptin receptor mutations that render them obese, hyperphagic and hyperinsulinemic. In the above models, viral vectors expressing AVP, leptin receptor b and proopiomelanocortin, respectively were stereotaxically injected in the relevant hypothalamic regions. In rats, aging brings about a progressive degeneration and loss of hypothalamic tuberoinfundibular dopaminergic neurons, which are involved in the tonic inhibitory control of prolactin secretion and lactotrophic cell proliferation. Stereotaxic injection of an adenoviral vector expressing Insulin-like Growth Factor-I (IGF-I) was able to correct their chronic hyperprolactinemia and restore tuberoinfundibular dopaminergic (TIDA) neuron numbers. In young and old F-344 male rats, Glial Cell Line-derived Neurotrophic Factor (GDNF) gene delivery in the hypothalamus induced body weight loss. These results suggest that further implementation of gene therapy strategies in neuroendocrine models may be highly rewarding.

A Rat Treated with Mesenchymal Stem Cells Lives to 44 Months of Age.

There is a growing interest in the potential of mesenchymal stem cells (MSCs) for implementing regenerative medicine. We assessed the effect of intravenous administration of human bone marrow-derived MSC on the life span of a single Sprague-Dawley female rat. The treatment was started when the rat was 6 months old and the cells were administered every 2 weeks afterward. The treatment did not induce any obvious changes in body growth or behavior and the rat showed the typical age changes for this strain, except that, unlike intact counterparts, the animal did not develop mammary tumors or pituitary gland hyperplasia. The more remarkable effect of the treatment was on life span, which was 44 months compared with an average of 36 months for intact laboratory rats. We conclude that despite the low N value, it is likely that the MSC treatment was responsible for the exceptionally long survival of the rat. The potential rewards of confirming the present findings warrant further studies involving higher N values.

Studies on in vivo gene transfer in pituitary tumors using herpes-derived and adenoviral vectors.

Suicide gene therapy has met limited success for the treatment of rat pituitary tumors. In order to determine the cause of primary pituitary tumor resistance to suicide gene therapy, we studied the transgene expression of an adenoviral (Ad.RSV.beta gal.nls) and a herpes simplex virus-derived (tsK/beta-gal) vector, both harboring the beta-galactosidase reporter gene in rat prolactinomas. Rats carrying experimental prolactinomas received bilateral 1 microl intrapituitary injections of either saline (saline group), 5 x 10(5) plaque-forming units (pfu) tsK/beta-gal (HSV Group) or 5 x 10(5) pfu Ad.RSV.beta gal.nls (RAd Group). Two or seven days later the tumors were examined. Macroscopic inspection of glands injected with either vector showed that the tissue expressing beta-gal was concentrated at the ventral area around the site reached by the tip of the needle. Almost no transgene expression was observed in other sites. Cellularity and lactotrophic cell density was not affected by saline or virus injection. In the injected areas, apoptotic levels were (x +/-S.E.M.): 9.3+/-0.5, 22.1+/-1.1 and 31.7+/-1.4%, for the saline, RAd and HSV groups, respectively. Serum prolactin and growth hormone levels were not affected by virus injection. We conclude that the low diffusibility of viral suspensions in the pituitary tissue may constitute a significant obstacle for achieving full remission of in situ pituitary tumors in rats.

Hypophysiotropic activity of histone H3 in vitro.

To assess the effect of histone H3 on pituitary hormone secretion, rat anterior pituitary (AP) cells were used and growth hormone, prolactin, thyrotropin, luteinizing hormone and follicle stimulating hormone measured by radioimmunoassay. Incubation of cells with H3 (1, 6, and 30 microM) stimulated the release of all five hormones in a dose-dependent manner. This effect was blocked by preincubation of H3 with an anti-H3 antibody. Incubation of AP cells with 6 microM H3 in the presence of specific AP hormone secretagogues (GRP-6, thyrotropin-releasing hormone (TRH), gonadotropin-releasing hormone (GnRH)) showed additive effects on hormone secretion. Pharmacological experiments suggested that calcium- and diacylglycerol- (DAG) associated pathways, but not cAMP, participate in the hypophysiotropic activity of H3. Our results confirm previous evidence that histones may act as hypophysiotropic signals.

Estrogen inhibits tuberoinfundibular dopaminergic neurons but does not cause irreversible damage.

Dopaminergic neurons of the hypothalamic tuberoinfundibular dopaminergic (TIDA) system exert a tonic inhibitory control on prolactin (PRL) secretion whereas estrogen, known to inhibit TIDA neuron function, has been postulated to be toxic to TIDA neurons when it is chronically high. In order to determine whether estrogen in high doses can cause permanent damage to TIDA function, we submitted young female rats to continue high doses of estrogen administered, either centrally (intrahypothalamic estrogen implants) or peripherally (subcutaneous estrogen implants or weekly intramuscular (i.m.) injections for 7 weeks), subsequently withdrawing the steroid and observing the evolution of lactotrophes, serum PRL and TIDA neurons. Serum PRL was measured by radioimmunoassay whereas tyrosine hydroxylase positive (TH+) neurons and PRL cells were morphometrically assessed in sections of fixed hypothalami and pituitaries, respectively. After 30 days, hypothalamic estrogen implants induced a significant increase in serum PRL, whereas TH+ neurons were not detectable in the arcuate-periventricular hypothalamic (ARC) region of estrogen-implanted rats. Removal of implants on day 30 restored TH expression in the ARC and brought serum PRL back to basal levels 30 days after estrogen withdrawal. Subcutaneous or i.m. administration of estrogen for 7 weeks induced a marked hyperprolactinemia. However, 30 weeks after estrogen withdrawal, TH neuron numbers in the ARC were back to normal and serum PRL returned to basal levels. After peripheral but not central estrogen withdrawal, pituitary weight and lactotrophic cell numbers remained slightly increased. Our data suggest that estrogen even at high doses, does not cause permanent damage to TIDA neurons.

Thymulin gene therapy prevents the reduction in circulating gonadotropins induced by thymulin deficiency in mice.

Integrity of the thymus during perinatal life is necessary for a proper maturation of the pituitary-gonadal axis in mice and other mammalian species. Thus congenitally athymic (nude) female mice show significantly reduced levels of circulating gonadotropins, a fact that seems to be causally related to a number of reproductive derangements described in these mutants. Interestingly, a number of in vitro studies suggest that the thymic peptide thymulin may be involved in thymus-pituitary communication. To determine the consequences of low serum thymulin in otherwise normal animals, we induced short (8 days)- and long (33 days)-term thymulin deficiency in C57BL/6 mice by neonatally injecting (intraperitoneally) an anti-thymulin serum and assessed their circulating gonadotropin levels at puberty and thereafter. Control mice received an irrelevant antiserum. Gonadotropins were measured by radioimmunoassay and thymulin by bioassay. Both long- and short-term serum thymulin immunoneutralization resulted in a significant reduction in the serum levels of gonadotropins at 33 and 45 days of age. Subsequently, we injected (intramuscularly) an adenoviral vector harboring a synthetic DNA sequence (5'-ATGCAAGCCAAATCTCAAGGTGGATCCAACTAGTAG-3') encoding a biologically active analog of thymulin, methionine-FTS, in newborn nude mice (which are thymulin deficient) and measured circulating gonadotropin levels when the animals reached 52 days of age. It was observed that neonatal thymulin gene therapy in the athymic mice restored their serum thymulin levels and prevented the reduction in circulating gonadotropin levels that typically emerges in these mutants after puberty. Our results indicate that thymulin plays a relevant physiological role in the thymus-pituitary-gonadal axis.

Hormonas tímicas como mediadoras de la integración inmunogonadotropa / Thymic hormones as mediators of the inmunogonadotroph integration

Existe significativa evidencia sobre la existencia de un eje timo-hipofiso-gonadal. En razón de que estudios previos de los autores habían demostrado que la Hormona Homeostática Tímica, un dímero de histonas H2A y H2B, posee múltiples efectos in vivo sobre la secreción de hormonas hipofisarias, resultó de interés evaluar el efecto in vitro de distintas preparaciones tímicas y proteínas nucleares relacionadas, sobre la liberación de prolactina (Prl), hormona foliculoestimulante (FSH) y hormona luteinizante (LH). Células hipofisarias frescas de ratas hembras se dispersaron con colagenasa y se empaquetaron en una columna de Biogel P-2 mantenida a 37oC. Las células se perifundieron continuamente con medios EBSS, o,5 por ciento de BSA, 1 por ciento de ácido ascórbico y 50 IU de aprotinina/ml (medio de perifusión, MP). Las sustancias a ser testeadas (estímulos) se disolvieron en MP, perifundiéndose en un volumen de 1,5 ml por estímulo a través del circuito de perifusión, al final del cual se recogieron fracciones de 1 ml. Las hormonas liberadas se dosaron por radioinmunoensayo. La viabilidad de las células dispersas osciló entre 84 y 96 porciento. Distintas diluciones de extractos de eminencia media de rata generaron, para cada hormona, una respuesta estimulatoria dosis-dependiente. En general, tanto las preparaciones de histona H2A como las de nucleohistona (ambas a una concentración de 500 µg/ml) indujeron picos secretorios significativos de LH, FSH y Prl, siendo los más elevados los correspondientes a Prl. Asimismo, la hormona tímica timulina y sobrenadantes provenientes de cultivo de células epiteliales tímicas de rata y ratón, pero no la timosina fracción ÷ o el péptido tímico MB-35, resultaron estimulatorios. Los resultados del presente trabajo sugieren que ciertos productos tímicos podrían participar en la integración inmuno-gonadotropa, actuando como señales hipofisotropas

Corticotropin-releasing (CRH) activity of thymic peptides on CRH-insensitive corticotropic tumor cells

Se sabe que ciertas preparaciones tímicas son capaces de estimular la liberación de corticotrofina (ACTH) en células hipofisarias. No resulta claro, sin embargo, si este efecto es mediado por el receptor para la hormona liberadora de ACTH (CRH). En el presente estudio se observó que la timosina fracción cinco (TF5), el péptido tímico MB-35 y posiblemente ciertas histonas de timo de ternera son capaces de estimular la liberación de ACTH en una sublínea insensible al CRH derivada de la línea tumoral coricotropa AtT20 y por lo tanto denominada AtT20(Cl). El rango de concentraciones efectivas en el cual TF5 y MB-35 mostraron un efecto dosis-dependiente sobre la liberación de ACTH fue de 100 a 2000 µg/ml y de 10 a 100 mg/ml para TF5 y MB-35, respectivamente. Aunque ninguna de estas preparaciones indujo cambios significativos en el contenido intracelular de ACTH en las células AtT20(Cl), se observó una tendencia hacia la depleción a las dosis más altas de RF5. Los resultados obtenidos sugieren que ciertos péptidos tímicos son capaces de estimular la liberación de ACTH en células corticotropas por un mecanismo independiente del receptor par CRH